Unstable Angina
Conditions
Keywords
Unstable Angina, Traditional Chinese Medicine
Brief summary
This study evaluates the clinical efficacy of the famous prescription in the treatment of unstable angina pectoris. All of the patients will be divided into 4 arms according to their syndrome type. One of the arms will be treated by conventional western medicine, the other three will be treated by different Chinese herbal medicine prescription at the base of conventional western medicine.
Detailed description
Xuefu Zhuyu Decoction has the function of activating qi and promoting blood circulation, which will be used to treat patients with qi stagnation and blood stasis syndrome. GualouXiebaiBanxia Decoction compounded with Danshen Decoction has the effect of promoting blood circulation and resolving phlegm, so it will be used for patients taht belong to phlegm and blood stasis type. Shuanghe Decoction has the function of supplementing Qi and activating blood circulation, which will be used to treat patients with Qi deficiency and blood stasis syndrome.
Interventions
Including aspirin and clopidogrel, etc.
Mainly including statins
Mainly including nitrates
Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
Sponsors
Jun Li
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
35 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Participants diagnosed with coronary heart disease through coronary angiography or coronary CTA; Patients have at least one of these symptoms: 1. The stability of the nature of angina pectoris changes, that is, frequent attacks of angina pectoris, serious degree and prolonged duration; 2. Angina pectoris during rest; 3. The recent occurrence of angina pectoris caused by mild physical activity in the last month.
Exclusion criteria
* Patients dignosed with stable angina; Patients with acute myocardial infarction; Chest pain caused by congenital heart disease, valvular heart disease, severe neurosis or arrhythmia; The heart function grade is III or IV; Patients with acute cerebral infarction; Patients complicated with other serious primary diseases; Patients with acute infection in recent 2 weeks; Uncontrolled hypertension (the resting blood pressure \>160/95mmHg within one week); Diabetics emerged with serious diabetic complications; Patients can't finish the questionnaire due to abnormal mental and nervous or mental disorders; Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | Six months after drug intervention | Death caused by cardiovascular disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Myocardial enzymes | At baseline and 4 weeks after drug intervention | The unit is mmol/L |
| Blood lipid | At baseline and 4 weeks after drug intervention | The unit is mmol/L. |
| Treadmill exercise test | At baseline and 4 weeks after drug intervention | The result will be positive or negative |
| The incidence of myocardial infarction or heart failure | Six months after drug intervention | — |
Contacts
Primary ContactPanpan Tian
Outcome results
None listed